SCAI: Ixmyelocel-T studied for dilated cardiomyopathy

May 15, 2012
SCAI: ixmyelocel-T studied for dilated cardiomyopathy

(HealthDay) -- For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year, according to a study presented at the Society for Cardiovascular Angiography and Interventions 2012 Scientific Sessions, held from May 9 to 12 in Las Vegas.

Timothy Henry, M.D., from the Minneapolis Heart Institute Foundation at Abbot Northwestern Hospital in Minnesota, and colleagues conducted a phase 2a trial to assess the safety and preliminary efficacy of intramyocardial delivery of ixmyelocel-T in 22 patients with ischemic and non-ischemic dilated cardiomyopathy. Participants with New York Heart Association (NYHA) Class III/IV, a of 30 percent, and limited treatment options were randomly allocated in a 2:1 ratio to ixmyelocel-T or control. were cultured to expand the number of activated macrophages and and then injected into the after cardiac mapping. Safety and efficacy were assessed at baseline and at three, six, and 12 months.

The researchers found that there were no procedural complications and no between-group differences in adverse events. Improved clinical outcomes were seen in patients with ischemic dilated cardiomyopathy, with a mean number of 0.22 major adverse cardiovascular events, versus 1.67 in control patients. Compared with controls or patients with non-ischemic dilated cardiomyopathy, more patients with ischemic dilated cardiomyopathy had improvements in NYHA Class, six-minute walk distance, and ejection fraction.

"Treatment with ixmyelocel-T was well tolerated and patients who received the cell therapy showed improved symptoms after one year," Henry said in a statement. "The results provide a strong basis for a larger clinical trial of this treatment in patients with dilated cardiomyopathy."

Several authors disclosed financial ties to biotechnology companies, including Aastrom Biosciences, which funded the study.

Explore further: Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure

More information: Press Release
More Information

Related Stories

Recommended for you

Few heart attack survivors get recommended physical activity

March 1, 2017

Only 16 percent of heart attack survivors get the recommended amount of physical activity in the weeks after hospitalization, according to a study by researchers at Columbia University Medical Center (CUMC) and NewYork-Presbyterian.

Study clarifies risky decision making during a heart attack

February 28, 2017

In a recent study to determine why some individuals who experience symptoms for acute coronary syndrome decide to seek medical attention more quickly than others, a University of Oklahoma researcher has identified numeracy—the ...

Study finds stroke care faster for men than women

February 24, 2017

(HealthDay)—Male stroke patients are more than twice as likely as female patients to receive clot-busting stroke treatment within 30 minutes of hospital arrival, a new study reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.